MiNK Therapeutics (NASDAQ: INKT) director receives RSU grants instead of cash retainers
Rhea-AI Filing Summary
WIINBERG ULF reported acquisition or exercise transactions in this Form 4 filing.
MiNK Therapeutics director Ulf Wiinberg reported stock-based board compensation rather than open-market trading. On June 1, 2026, he received 1,131 shares of Common Stock at $12.38 per share as a grant in lieu of cash retainers, bringing his direct holdings to 22,650 shares.
The filing also shows a prior grant of 1,285 shares on March 2, 2026 at $10.90 per share, with 21,519 shares held directly after that award. In addition, 27,830 shares are held indirectly in an irrevocable trust for the benefit of his family. Footnotes state these restricted stock units vest one month after grant and that the Q1 2026 grant was filed late due to an administrative error.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,416 shares
Net Buy
3 txns
Insider
WIINBERG ULF
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 1,131 | $12.38 | $14K |
| Grant/Award | Common Stock | 1,285 | $10.90 | $14K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 22,650 shares (Direct);
Common Stock — 27,830 shares (Indirect, See footnote)
Footnotes (3)
- F1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
- F2. Shares are held in an irrevocable trust for the benefit of Mr. Wiinberg's family.
- F3. Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.
Key Figures
June 1, 2026 grant: 1,131 shares at $12.38
Direct holdings after June 1, 2026: 22,650 shares
March 2, 2026 grant: 1,285 shares at $10.90
+2 more
5 metrics
June 1, 2026 grant
1,131 shares at $12.38
Common Stock awarded in lieu of cash retainers
Direct holdings after June 1, 2026
22,650 shares
Total Common Stock held directly following latest grant
March 2, 2026 grant
1,285 shares at $10.90
Common Stock award replacing Q1 2026 board cash compensation
Direct holdings after March 2, 2026
21,519 shares
Direct Common Stock position after earlier grant
Indirect trust holdings
27,830 shares
Common Stock held in irrevocable family trust
Key Terms
restricted stock units, in lieu of cash retainers, irrevocable trust, board and committee compensation, +1 more
5 terms
restricted stock units financial
"The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
in lieu of cash retainers financial
"The RSUs were received in lieu of cash retainers for board and committee compensation."
irrevocable trust financial
"Shares are held in an irrevocable trust for the benefit of Mr. Wiinberg's family."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
board and committee compensation financial
"The RSUs were received in lieu of cash retainers for board and committee compensation."
administrative error other
"Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did MiNK Therapeutics (INKT) director Ulf Wiinberg report in this Form 4?
He reported stock-based board compensation, not market buying or selling. The filing shows two awards of common stock granted in lieu of cash retainers, plus indirect holdings in a family trust, clarifying his direct and indirect ownership positions in MiNK Therapeutics.
What prior stock award to Ulf Wiinberg does the MiNK Therapeutics (INKT) Form 4 show?
It shows a March 2, 2026 grant of 1,285 common shares at $10.90 per share. This award also represented restricted stock units received instead of cash board and committee retainers, increasing his direct equity-based compensation from MiNK Therapeutics.
What indirect MiNK Therapeutics (INKT) holdings are reported for Ulf Wiinberg?
The Form 4 reports 27,830 shares of Common Stock held indirectly in an irrevocable trust for the benefit of his family. This trust position is separate from his directly held shares and is disclosed as indirect ownership with a specific footnote explanation.
Why does the MiNK Therapeutics (INKT) Form 4 mention an administrative error?
A footnote explains that restricted stock units for Q1 2026 board and committee compensation were not filed on time due to an administrative error. The current Form 4 therefore includes information that should have been reported earlier, correcting the delayed disclosure.
How do the RSU grants in the MiNK Therapeutics (INKT) Form 4 vest?
Footnotes state that each restricted stock unit represents one common share and will vest one month after the grant date. This means Wiinberg’s RSU-based board compensation converts into freely held shares shortly after each award is granted by the company.